Pharmacotherapy of Obesity

Abstract

Obesity has become a significant health problem in industrialised and developing countries, and despite all nutritional and behavioural approaches, its prevalence is still increasing. In recent years, the identification and characterisation of central and peripheral mechanisms involved in the regulation of energy balance has made remarkable progress and provided numerous targets for novel antiobesity agents. However, only few antiobesity drugs are on the market and not many compounds have entered clinical development. In the present review, the clinically available agents are discussed and their pharmacological profiles are compared. Some of the drugs that are currently in clinical development are mentioned as examples of the possible future range of antiobesity agents. Selected topics in drug discovery are presented to illustrate novel targets and concepts for the pharmacotherapy of obesity.

Appetite - energy balance - metabolism - adipose tissue - drugs

References

• 1 Ahima RS, Osei SY. Leptin signaling.  Physiol Behav. 2004;  81 223-241
• 2 Argyropoulos G, Harper ME. Uncoupling proteins and thermoregulation.  J Appl Physiol. 2002;  92 2187-2198
• 3 Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a systematic review.  Arch Intern Med. 2004;  164 994-1003
• 4 Aucott L, Poobalan A, Smith WC, Avenell A, Jung R, Broom J. Effects of weight loss in overweight/obese individuals and long-term hypertension outcomes: a systematic review.  Hypertension. 2005;  45 1035-1041
• 5 Badman MK, Flier JS. The gut and energy balance: visceral allies in the obesity wars.  Science. 2005;  307 1909-1914
• 6 Balthasar N, Dalgaard LT, Lee CE, Yu J, Funahashi H, Williams T, Ferreira M, Tang V, McGovern RA, Kenny CD, Christiansen LM, Edelstein E, Choi B, Boss O, Aschkenasi C, Zhang CY, Mountjoy K, Kishi T, Elmquist JK, Lowell BB. Divergence of melanocortin pathways in the control of food intake and energy expenditure.  Cell. 2005;  123 493-505
• 7 Batkai S, Pacher P, Osei-Hyiaman D, Radaeva S, Liu J, Harvey-White J, Offertaler L, Mackie K, Rudd MA, Bukoski RD, Kunos G. Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension.  Circulation. 2004;  110 1996-2002
• 8 Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS, Ghatei MA, Bloom SR. Inhibition of food intake in obese subjects by peptide YY3-36.  N Engl J Med. 2003;  349 941-948
• 9 Bays HE. Current and investigational antiobesity agents and obesity therapeutic treatment targets.  Obes Res. 2004;  12 1197-1211
• 10 Birkenfeld AL, Schroeder C, Pischon T, Tank J, Luft FC, Sharma AM, Jordan J. Paradoxical effect of sibutramine on autonomic cardiovascular regulation in obese hypertensive patients-sibutramine and blood pressure.  Clin Auton Res. 2005;  15 200-206
• 11 Boggiano MM, Chandler PC, Oswald KD, Rodgers RJ, Blundell JE, Ishii Y, Beattie AH, Holch P, Allison DB, Schindler M, Arndt K, Rudolf K, Mark M, Schoelch C, Joost HG, Klaus S, Thone-Reineke C, Benoit SC, Seeley RJ, Beck-Sickinger AG, Koglin N, Raun K, Madsen K, Wulff BS, Stidsen CE, Birringer M, Kreuzer OJ, Deng XY, Whitcomb DC, Halem H, Taylor J, Dong J, Datta R, Culler M, Ortmann S, Castaneda TR, Tschop M. PYY3-36 as an antiobesity drug target.  Obes Rev. 2005;  6 307-322
• 12 Boss O, Bergenhem N. Adipose targets for obesity drug development.  Expert Opin Ther Targets. 2006;  10 119-134
• 13 Bouskila M, Pajvani UB, Scherer PE. Adiponectin: a relevant player in PPAR γ-agonist-mediated improvements in hepatic insulin sensitivity?.  Int J Obes (Lond). 2005;  29 S17-S23
• 14 Bray GA, Greenway FL. Current and potential drugs for treatment of obesity.  Endocr Rev. 1999;  20 805-875
• 15 Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S.  adults. N Engl J Med. 2003;  348 1625-1638
• 16 Chan CB, Saleh MC, Koshkin V, Wheeler MB. Uncoupling protein 2 and islet function.  Diabetes. 2004;  53 S136-S142
• 17 Chiesi M, Huppertz C, Hofbauer KG. Pharmacotherapy of obesity: targets and perspectives.  Trends Pharmacol Sci. 2001;  22 247-254
• 18 Collins S, Cao W, Robidoux J. Learning new tricks from old dogs: beta-adrenergic receptors teach new lessons on firing up adipose tissue metabolism.  Mol Endocrinol. 2004;  18 2123-2131
• 19 Cone RD. Anatomy and regulation of the central melanocortin system.  Nat Neurosci. 2005;  8 571-578
• 20 Cummings DE, Foster-Schubert KE, Overduin J. Ghrelin and energy balance: focus on current controversies.  Curr Drug Targets. 2005;  6 153-169
• 21 Curran MP, Scott LJ. Orlistat: a review of its use in the management of patients with obesity.  Drugs. 2004;  64 2845-2864
• 22 Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, Heimburger DC, Lucas CP, Robbins DC, Chung J, Heymsfield SB. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial.  JAMA. 1999;  281 235-242
• 23 Degen L, Oesch S, Casanova M, Graf S, Ketterer S, Drewe J, Beglinger C. Effect of peptide YY(3-36) on food intake in humans.  Gastroenterology. 2005;  129 1430-1436
• 24 Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.  N Engl J Med. 2005;  353 2121-2134
• 25 Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance.  Nat Neurosci. 2005;  8 585-589
• 26 Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal pt-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction.  Int J Impot Res. 2004;  16 51-59
• 27 Dulloo AG. Dietary supplements and herbal preparations. In: Hofbauer KG, Keller U, Boss O (eds). Pharmacotherapy of Obesity. Options and Alternatives. Boca Raton: CRC Press 2004: 405-419
• 28 Fishman AP. Aminorex to fen/phen.  An epidemic foretold. Circulation. 1999;  99 156-161
• 29 Flegal KM. Epidemiologic aspects of overweight and obesity in the United States.  Physiol Behav. 2005;  86 599-602
• 30 Flier JS. Obesity wars: molecular progress confronts an expanding epidemic.  Cell. 2004;  116 337-350
• 31 Greenway FL, Heber D. Herbal and alternative approaches to obesity. In: Bray GA, Bouchard C (eds). Handbook of Obesity 2nd edn. New York: Marcel Dekker, Inc. 2004: 329-358
• 32 Grundy SM, Cleeman JI, Daniels SR, Donate KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith Jr SC, Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement.  Circulation. 2005;  112 2735-2752
• 33 Gura T. Obesity drug pipeline not so fat.  Science. 2003;  299 849-852
• 34 Halatchev IG, Cone RD. Peripheral administration of PYY_3-36 produces conditioned taste aversion in mice.  Cell Metabolism. 2005;  1 159-168
• 35 Halford JC. Clinical pharmacotherapy for obesity: current drugs and those in advanced development.  Curr Drug Targets. 2004;  5 637-646
• 36 Harper JA, Dickinson K, Brand MD. Mitochondrial uncoupling as a target for drug development for the treatment of obesity.  Obes Rev. 2001;  2 255-265
• 37 Harper M-E, Dent R, Tesson F, McPherson R. Targeting thermogenesis in the development of antiobesity drugs. In: Hofbauer KG, Keller U, Boss O (eds). Pharmacotherapy of Obesity. Options and alternatives. Boca Raton: CRC Press 2004: 363-383
• 38 Haslam DW, James WP. Obesity.  Lancet. 2005;  366 1197-1209
• 39 Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM. Prevalence of overweight and obesity among us children, adolescents, and adults, 1999-2002.  JAMA. 2004;  291 2847-2850
• 40 Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD 9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice.  Endocrinology. 2001;  142 5182-5189
• 41 Herzog H. Neuropeptide Y and energy homeostasis: insights from y receptor knockout models.  Eur J Pharmacol. 2003;  480 21-29
• 42 Hesselink MK, Mensink M, Schrauwen P. Human uncoupling protein-3 and obesity: an update.  Obes Res. 2003;  11 1429-1443
• 43 Heymsfield SB, Greenberg AS, Fujioka K, Dixon RM, Kushner R, Hunt T, Lubina JA, Patane J, Self B, Hunt P, McCamish M. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial.  JAMA. 1999;  282 1568-1575
• 44 Hauner H. Orlistat. In: Hofbauer KG, Keller U, Boss O (eds). Pharmacotherapy of Obesity. Options and Alternatives. Boca Raton: CRC Press 2004: 219-243
• 45 Juurhnk DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Re-delmeier DA. Rates of hyperkalemia after publication of the randomized aldactone evaluation study.  N Engl J Med. 2004;  351 543-551
• 46 Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.  Diabetes Care. 2005;  28 2289-2304
• 47 Katz DL. Competing dietary claims for weight loss: finding the forest through truculent trees.  Annu Rev Public Health. 2005;  26 61-88
• 48 Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.  N Engl J Med. 2002;  346 393-403
• 49 Kolanowski J. A risk-benefit assessment of antiobesity drugs.  Drug Saf. 1999;  20 119-131
• 50 Korner J, Aronne LJ. Pharmacological approaches to weight reduction: therapeutic targets.  J Clin Endocrinol Metab. 2004;  89 2616-2621
• 51 Kuo JJ, Silva AA, Hall JE. Hypothalamic melanocortin receptors and chronic regulation of arterial pressure and renal function.  Hypertension. 2003;  41 768-774
• 52 Lafontan M. Fat cells: afferent and efferent messages define new approaches to treat obesity.  Annu Rev Pharmacol Toxicol. 2005;  45 119-146
• 53 Lazar MA. How obesity causes diabetes: not a tall tale.  Science. 2005;  307 373-375
• 54 Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight.  N Engl J Med. 1995;  332 621-628
• 55 Levine JA, Lanningham-Foster LM, McCrady SK, Krizan AC, Olson LR, Kane PH, Jensen MD, Clark MM. Interindividual variation in posture allocation: possible role in human obesity.  Science. 2005;  307 584-586
• 56 Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR, Hilton L, Suttorp M, Solomon V, Shekelle PG, Morton SC. Meta-analysis: pharmacologic treatment of obesity.  Ann Intern Med. 2005;  142 532-546
• 57 Maggard MA, Shugarman LR, Suttorp M, Maglione M, Sugerman HJ, Livingston EH, Nguyen NT, Li Z, Mojica WA, Hilton L, Rhodes S, Morton SC, Shekelle PG. Meta-analysis: surgical treatment of obesity.  Ann Intern Med. 2005;  142 547-559
• 58 Mashiko S, Ishihara A, Gomori A, Moriya R, Ito M, Iwaasa H, Matsuda M, Feng Y, Shen Z, Marsh DJ, Bednarek MA, MacNeil DJ, Kanatani A. Antiobesity effect of a melanin-concentrating hormone 1 receptor antagonist in diet-induced obese mice.  Endocrinology. 2005;  146 3080-3086
• 59 Matsuzawa Y. Therapy insight: adipocytokines in metabolic syndrome and related cardiovascular disease.  Nat Clin Pract Cardiovasc Med. 2006;  3 35-42
• 60 Moller DE, Kaufman KD. Metabolic syndrome: a clinical and molecular perspective.  Annu Rev Med. 2005;  56 45-62
• 61 Mori H, Hanada R, Hanada T, Aki D, Mashima R, Nishinakamura H, Torisu T, Chien KR, Yasukawa H, Yoshimura A. Socs3 deficiency in the brain elevates leptin sensitivity and confers resistance to diet-induced obesity.  Nat Med. 2004;  10 739-743
• 62 Moyers SB. Medications as adjunct therapy for weight loss: approved and off-label agents in use.  J Am Diet Assoc. 2005;  105 948-959
• 63 Nawrocki AR, Scherer PE. Keynote review: the adipocyte as a drug discovery target.  Drug Discov Today. 2005;  10 1219-1230
• 64 Nisoli E, Carruba MO. Emerging aspects of pharmacotherapy for obesity and metabolic syndrome.  Pharmacol Res. 2004;  50 453-469
• 65 Nordheim U, Nicholson JR, Dokladny K, Dunant P, Hofbauer KG. Cardiovascular responses to melanocortin 4-receptor stimulation in conscious unrestrained normotensive rats.  Peptides. 2006;  27 438-443
• 66 O'Rahilly S, Yeo GS, Farooqi IS. Melanocortin receptors weigh in.  Nat Med. 2004;  10 351-352
• 67 Park A, Bloom SR. Peptides and obesity: the PYY3-36 story.  Regul Pept. 2004;  119 1-2
• 68 Pertwee RG. Cannabinoid pharmacology: the first 66 years.  Br J Pharmacol. 2006;  147 S163-S171
• 69 Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, Eckel RH. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. An update of the 1997 American Heart Association scientific statement on obesity and heart disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism.  Circulation. 2006;  113 898-918
• 70 Prentice AM. The emerging epidemic of obesity in developing countries.  Int J Epidemiol. 2006;  35 93-99
• 71 Ryan DH. Sibutramine. In: Hofbauer KG, Keller U, Boss O (eds). Pharmacotherapy of Obesity. Options and Alternatives. Boca Raton: CRC Press 2004: 245-266
• 72 Schmitz O, Brock B, Rungby J. Amylin agonists: a novel approach in the treatment of diabetes.  Diabetes. 2004;  53 S233-S238
• 73 Schwartz MW, Porte Jr D. Diabetes, obesity, and the brain.  Science. 2005;  307 375-379
• 74 Ste Marie L, Luquet S, Cole TB, Palmiter RD. Modulation of neuropeptide y expression in adult mice does not affect feeding.  Proc Natl Acad Sci USA. 2005;  102 18632-18637
• 75 Tsai AG, Wadden TA. Systematic review: an evaluation of major commercial weight loss programs in the United States.  Ann Intern Med. 2005;  142 56-66
• 76 Ueno H, Yamaguchi H, Kangawa K, Nakazato M. Ghrelin. A gastric peptide that regulates food intake and energy homeostasis.  Regul Pept. 2005;  126 11-19
• 77 Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the Rio-Europe Study.  Lancet. 2005;  365 1389-1397
• 78 Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Phelan S, Cato RK, Hesson LA, Osei SY, Kaplan R, Stunkard AJ. Randomized trial of lifestyle modification and pharmacotherapy for obesity.  N Engl J Med. 2005;  353 2111-2120
• 79 Wagner JA, Hu K, Bauersachs J, Karcher J, Wiesler M, Goparaju SK, Kunos G, Ertl G. Endogenous cannabinoids mediate hypotension after experimental myocardial infarction.  J Am Coll Cardiol. 2001;  38 2048-2054
• 80 Wessells H, Blevins JE, Vanderah TW. Melanocortinergic control of penile erection.  Peptides. 2005;  26 1972-1977
• 81 Wolfe BM, Morton JM. Weighing in on bariatric surgery: procedure use, readmission rates, and mortality.  JAMA. 2005;  294 1960-1963
• 82 Yach D, Stuckler D, Brownell KD. Epidemiologic and economic consequences of the global epidemics of obesity and diabetes.  Nat Med. 2006;  12 62-66
• 83 Yanagisawa T, Sato T, Yamada H, Sukegawa J, Nunoki K. Selectivity and potency of agonists for the three subtypes of cloned human beta-adrenoceptors expressed in Chinese hamster ovary cells.  Tohoku J Exp Med. 2000;  192 181-193
• 84 Yanovski SZ, Yanovski JA. Obesity.  N Engl J Med. 2002;  346 591-602

Correspondence